Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.5Last Year’s EPS
0.03Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 19, 2025
|% Change Since: 16.55%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, successful VYJUVEK launch, and robust pipeline developments. However, challenges in patient compliance, operational delays, and increased expenses were noted. The company's strategic plans for global expansion and future growth provide a positive outlook.Company Guidance
During the Krystal Biotech Q4 2024 earnings call, the company provided guidance on various financial and operational metrics. They reported a net income per share of $3.12 for 2024, a significant increase from $0.40 per share in 2023, marking the sixth consecutive quarter of positive EPS and the fourth of sequential earnings growth. The company achieved $341 million in net revenue within 18 months post-launch, with $91.1 million in Q4 alone, bringing total 2024 revenue to $290.5 million. They also noted a gross margin of 95%. Krystal Biotech outlined objectives for 2025, including the VYJUVEK launch in the EU and Japan, expansion of their CF and A1AT programs, and preparation for the B-VEC launch to treat eye lesions in DEB patients. The company anticipates increasing operating expenses to between $150 million and $175 million, excluding stock-based compensation, due to anticipated international launches and expanded pipeline programs. Cash on hand was reported at $344.9 million, with total cash and investments at $749.6 million, reflecting a $55 million increase from the previous quarter.Strong Financial Performance
Net income per share was $3.12, up from $0.40 in 2023, marking the sixth straight quarter of positive EPS and the fourth consecutive quarter of sequential earnings growth.
Successful Launch of VYJUVEK
VYJUVEK U.S. launch continues to track in the top tier of rare disease launches with $341 million in net revenue within 18 months of launch and sequential revenue growth for six straight quarters.
Reimbursement Approvals Milestone
The company crossed 500 reimbursement approvals nationwide, with more than 510 patients approved as of February, indicating strong demand and market penetration.
Expanded Global Market Plans
Plans for VYJUVEK launch in Europe and Japan with anticipated regulatory approvals, targeting over 1,000 identified DEB patients in Germany and France alone.
Robust Pipeline Developments
Progress in gene delivery programs for cystic fibrosis, alpha-1 antitrypsin deficiency, and non-small cell lung cancer, with strong early signs of efficacy and validation of the lung as a second target tissue.
---
KRYS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KRYS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 19, 2025 | $156.69 | $176.17 | +12.43% |
| Nov 04, 2024 | $176.39 | $170.85 | -3.14% |
| Aug 05, 2024 | $191.94 | $180.71 | -5.85% |
| May 06, 2024 | $161.10 | $156.94 | -2.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Krystal Biotech (KRYS) report earnings?
Krystal Biotech (KRYS) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Krystal Biotech (KRYS) earnings time?
Krystal Biotech (KRYS) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KRYS EPS forecast?
KRYS EPS forecast for the fiscal quarter 2025 (Q1) is 1.5.
---